We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Wine-Related Cancer Treatment Shows Promise Against Neuroblastomas

By LabMedica International staff writers
Posted on 12 Mar 2009
Resveratrol--the intriguing substance that seems to make red wine heart-healthy--is being proposed for clinical trials later in 2009 as a treatment against neuroblastoma, a type of cancer that affects infants and young children.

Dr. Arthur Polans, professor of ophthalmology and visual sciences at the University of Wisconsin School of Medicine and Public Health (UW; Madison, USA) and the UW Paul P. Carbone Comprehensive Cancer Center, has been studying the substance for about five years, and has been using it successfully to treat several types of cancer in mice. His research group has applied for permission to use it to treat neuroblastoma, a nervous-system cancer that mostly affects infants and children.

"Resveratrol is a promising treatment for young children because it's not toxic to healthy cells, only to cancer cells,'' Dr. Polans said. "How do you treat infants without causing other problems in the years to come? That is the kind of question that intrigues us.”

Because it seems to kill cancer kills while leaving healthy tissue alone, resveratrol is also being looked at to treat ocular or uveal melanoma, a cancer of the eye that can lie dormant for many years before metastasizing and becoming fatal. So far, there are no good treatments for melanoma that begins in the colored tissues of the eye; it doesn't respond the same way as melanoma that begins in the skin. "It's one of those rotten cancers,'' Dr. Polans noted. "We don't know what causes it and we don't know how to treat it effectively.”

While the cancers are very different, adults who develop melanoma of the eye have something in common with babies who develop neuroblastoma--they may live for a long time after their diagnosis, so potential treatments shouldn't cause other health problems.

"What neuroblastoma and uveal melanoma have in common is the factor of time,” said Dr. Polans. "Ideally, you'd like to be able to treat them aggressively at first, and then treat them with lower doses of a non-toxic compound over time. Otherwise, you run the risk of damage to vital organs or an increase in secondary tumors.”

So far, the Polans lab has shown that resveratrol shrinks tumors and kills malignant cells in five types of cancer: skin melanoma, breast cancer, neuroblastoma, ocular melanoma and retinoblastoma. A poster outside Dr. Polans' office shows a mouse with a large neuroblastoma tumor that is then shrunken to nothing by resveratrol. "Mice that were treated with resveratrol are healthy, gain weight, and don't seem to have side effects,'' he said, "but when you look at the cancer cells, they're dying.”

Dr. Polans' lab has also done a lot of essential research on resveratrol, developing new forms of the compound that are more potent, and active in the body for longer than the common forms of the substance.

If it shows to be effective, resveratrol will join a large class of cancer-fighting compounds derived from plants, including taxol, which comes from yew trees, and etopside, derived from the mayapple. Resveratrol, which can be derived from grape skins, is also seen as the substance at work in the so-called "French Paradox,'' in which French hearts stay healthy (due to drinking red wine) in spite of all the high fat foods consumed.

"About 70% of new chemotherapeutics are derived from natural products or based on their structures,'' concluded Dr. Polans. "There's a lot of interest worldwide in finding new substances from plants and other natural sources, including microbes from the soil and a variety of species from the ocean.”

Related Links:

University of Wisconsin School of Medicine and Public Health



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Hemoglobin Testing System
VARIANTnbs
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Molecular Diagnostics

view channel
Image: Molecular PCR-grade detection of Lyme bacteria right at the tick bite (Photo courtesy of En Carta Diagnostics)

Groundbreaking Molecular Diagnostic Kit to Provide Lyme Disease Detection in Minutes

Lyme disease, transmitted through tick bites, is a bacteria-caused illness that impacts 1.2 million individuals annually. The standard methods for diagnosing this disease include clinical examinations,... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The novel test uses an existing diagnostic procedure as its basis to target the Epstein Barr Virus (Photo courtesy of 123RF)

Blood Test Measures Immune Response to Epstein-Barr Virus in MS Patients

Multiple sclerosis (MS) is a chronic neurological condition for which there is currently no cure. It affects around three million people globally and ranks as the second most common cause of disability... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more

Pathology

view channel
Image: Insulin proteins clumping together (Photo courtesy of Jacob Kæstel-Hansen)

AI Tool Detects Tiny Protein Clumps in Microscopy Images in Real-Time

Over 55 million individuals worldwide suffer from dementia-related diseases like Alzheimer's and Parkinson's. These conditions are caused by the clumping together of the smallest building blocks in the... Read more

Industry

view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.